Clinical trial
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting…
NCT00080444 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00080444 |
|---|---|
| Title | Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Emetogenic Chemotherapy in Adolescent… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vomiting |
| Intervention type | Drug |
| Interventions | aprepitant, ondansetron, dexamethasone, placebo to aprepitant, placebo to dexamethasone, rescue medication |
| Enrollment | 50 |
| Start date | Apr 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Apr 2, 2004 |
| Last update posted | Aug 5, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: